Longitudinal cerebrospinal fluid biomarker trajectories along the Alzheimer's disease continuum in the BIOMARKAPD study

Introduction: Within-person trajectories of cerebrospinal fluid (CSF) biomarkers in Alzheimer's disease (AD) are not well defined. Methods: We included 467 subjects from the BIOMARKAPD study with at least two serial CSF samples. Diagnoses were subjective cognitive decline (n = 75), mild cogniti...

Descripción completa

Detalles Bibliográficos
Autores: Lleo, A, Alcolea, D, Martinez-Lage, P, Scheltens, P, Parnetti, L, Poirier, J, Simonsen, AH, Verbeek, MM, Rosa-Neto, P, Slot, RER, Tainta, M, Izaguirre, A, Reijs, BLR, Farotti, L, Tsolaki, M, Vandenbergue, R, Freund-Levi, Y, Verhey, FRJ, Clarimon, J, Fortea, J, Frolich, L, Santana, I, Molinuevo, JL, Lehmann, S, Visser, PJ, Teunissen, CE, Zetterberg, H, Blennow, K
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2019
País:España
Institución:Institut d’Investigació Biomèdica Sant Pau (IIB Sant Pau)
Repositorio:r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
OAI Identifier:oai:iibsantpau.fundanetsuite.com:p2652
Acceso en línea:https://iibsantpau.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=2652
https://cris.maastrichtuniversity.nl/en/publications/longitudinal-cerebrospinal-fluid-biomarker-trajectories-along-the
Access Level:acceso abierto
Palabra clave:Alzheimer
CSF
Tau
Amyloid
Neurofilaments
Inflammation
YKL-40
Descripción
Sumario:Introduction: Within-person trajectories of cerebrospinal fluid (CSF) biomarkers in Alzheimer's disease (AD) are not well defined. Methods: We included 467 subjects from the BIOMARKAPD study with at least two serial CSF samples. Diagnoses were subjective cognitive decline (n = 75), mild cognitive impairment (n = 128), and AD dementia (n = 110), and a group of cognitively unimpaired subjects (n = 154) were also included. We measured baseline and follow-up CSF levels of total tau (t-tau), phosphorylated tau (p-tau), YKL-40, and neurofilament light (NfL). Median CSF sampling interval was 2.1 years. Results: CSF levels of t-tau, p-tau, NfL, and YKL-40 were 2% higher per each year of baseline age in controls (P <. 001). In AD, t-tau levels were 1% lower (P <. 001) and p-tau levels did not change per each year of baseline age. Longitudinally, only NfL (P <. 001) and YKL-40 (P <. 02) increased during the study period. Discussion: All four CSF biomarkers increase with age, but this effect deviates in AD for t-tau and ptau. (C) 2019 the Alzheimer's Association. Published by Elsevier Inc. All rights reserved.

Similares en LA Referencia